WuXi PharmaTech Marks Second Quarter Of Earnings Rebound Following 2008's Devastating Loss
This article was originally published in The Pink Sheet Daily
The Shanghai-headquartered CRO is moving ahead with plans to invest about $60 million this year into completing the construction of a new drug safety testing center.
You may also be interested in...
Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued
BEIJING - Battered in succession by the unstable U.S. economy, faltering biologics customers and mounting losses by American subsidiary AppTec Laboratory Services, WuXi PharmTech reported a net loss of more than $60 million for 2008
BEIJING - Just three months after unveiling plans to create a joint venture facility for preclinical drug testing services on China's east coast, the Shanghai-headquartered WuXi PharmaTech and and Princeton, N.J.-based Covance have called off the deal
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.